APA (7th ed.) Citation

AM, K., CJ, P., K, E., H, K., & M, S. (2024). Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. The oncologist, 29(4), e507. https://doi.org/10.1093/oncolo/oyad300

Chicago Style (17th ed.) Citation

AM, Kahn, Perry CJ, Etts K, Kluger H, and Sznol M. "Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors." The Oncologist 29, no. 4 (2024): e507. https://doi.org/10.1093/oncolo/oyad300.

MLA (9th ed.) Citation

AM, Kahn, et al. "Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors." The Oncologist, vol. 29, no. 4, 2024, p. e507, https://doi.org/10.1093/oncolo/oyad300.